

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

CERTIFICATE OF FIRST CLASS MAILING (37 CFR 1.8)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the following date:

13 Nov 2006
Date

Gary R Fabian
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Williams, A., et al.	Confirmation No. 6889
Serial No.: 09/410,462	Art Unit: 1635
Filing Date: 1 October 1999	Examiner: J.E. Angell
Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS USING ADENOVIRAL MUTANTS	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing are an Information Disclosure Statement, a modified Form PTO-1449, listing seven U.S. Patents and two non-U.S. Patent publications, and copies of the two non-U.S. Patent publications.

Copies of the cited U.S. Patents are not enclosed pursuant the "Changes to Support Implementation of the United States Patent and Trademark Office 21st Century Strategic Plan," Federal Register, Vol. 69, No. 182.

The Examiner is respectfully requested to make this information of official record in the application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the


11/16/2006 SDEHDB1 00000018 150615 09410462
02 FC:1806 180.00 DA

like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

The Commissioner is hereby authorized to the fee (37 C.F.R. §1.17(p)) for this Information Disclosure Statement (\$180.00) to Deposit Account No. 15-0615 (**please reference ONYX1046.ORD**). No further fees are believed due. However, the Commissioner is authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 15-0615. This is not authorization to pay the Issue Fee.

Respectfully submitted,

Dated: 13 Nov 2006

By : 
Gary R. Fabian
Agent for Applicants
Registration No. 33,875

ONYX Pharmaceuticals, Inc.
2100 Powell Street
Emeryville, CA 94608
Phone: (510) 597-6502
Facsimile: (510) 597-6610

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



ONYX Dkt No.: ONYX1046.ORD

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 1 of 2

In the Application of: Williams, A., et al.

Confirmation No.: 6889

Serial No.: 09/410,462

Art Unit: 1635

Filed: 1 October 1999

Examiner: J.E. Angell

Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS
USING ADENOVIRAL MUTANTS

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	AD-01	5,677,178	October 14, 1997	McCormick			
	AD-02	5,801,029	September 1, 1998	McCormick			
	AD-03	5,846,945	December 8, 1998	McCormick			
	AD-04	5,856,181	January 5, 1999	McCormick			
	AD-05	6,296,845	October 2, 2001	Sampson- Johannes, et al.			
	AD-06	7,001,596	February 21, 2006	Johnson, et al.			
	AD-07	7,078,030	July 18, 2006	Johnson, et al.			

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO	
	BD-01							

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 2 of 2

In the Application of: Williams, A., et al.

Confirmation No.: 6889

Serial No.: 09/410,462

Art Unit: 1635

Filed: 1 October 1999

Examiner: J.E. Angell

Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS
USING ADENOVIRAL MUTANTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	CD-01	Berse, B., et al., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," Molec. Biol. Cell 1992 Feb;3(2):211-20
	CD-02	Warren, R.S., et al., "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis," J. Clin. Invest. 1995 Apr;95(4):1789-97

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.